Ekso Bionics (NASDAQ:EKSO) Research Coverage Started at StockNews.com

StockNews.com started coverage on shares of Ekso Bionics (NASDAQ:EKSO) in a research report report published on Wednesday. The brokerage issued a hold rating on the stock.

A number of other equities analysts have also recently commented on the company. Lake Street Capital lowered their target price on Ekso Bionics from $2.50 to $2.00 and set a “buy” rating for the company in a report on Tuesday, October 29th. HC Wainwright reissued a “buy” rating and issued a $9.00 price objective on shares of Ekso Bionics in a research note on Tuesday, January 14th.

Ekso Bionics Stock Performance

Shares of EKSO stock opened at $0.64 on Wednesday. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.14 and a current ratio of 2.81. The firm has a market cap of $14.17 million, a P/E ratio of -0.99 and a beta of 1.47. The firm’s 50 day moving average price is $0.67 and its 200-day moving average price is $0.93. Ekso Bionics has a one year low of $0.50 and a one year high of $2.42.

Ekso Bionics (NASDAQ:EKSO) last announced its earnings results on Monday, October 28th. The company reported ($0.10) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.02). Ekso Bionics had a negative net margin of 62.95% and a negative return on equity of 83.09%. The firm had revenue of $4.13 million during the quarter, compared to analysts’ expectations of $6.00 million. During the same period in the previous year, the firm earned ($0.24) EPS. As a group, equities research analysts predict that Ekso Bionics will post -0.48 EPS for the current year.

Ekso Bionics Company Profile

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.